Cargando…

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus

Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral antidiabetic agent for the treatment of type 2 diabetes mellitus. They increase endogenous levels of incretin hormones, which stimulate glucose-dependent insulin secretion, decrease glucagon secretion, and contribute to reducing postp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Sung-Ho, Yoo, Jung-Hwa, Lee, Woo Je, Park, Cheol-Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Diabetes Association 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069390/ https://www.ncbi.nlm.nih.gov/pubmed/27766241 http://dx.doi.org/10.4093/dmj.2016.40.5.339

Ejemplares similares

Gemigliptin: Newer Promising Gliptin for Type 2 Diabetes Mellitus
por: Gutch, Manish, et al.
Publicado: (2017)

Renoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice
por: Jung, Gwon-Soo, et al.
Publicado: (2016)

Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome
por: Seo, Jung Beom, et al.
Publicado: (2019)

A prospective cohort study on effects of gemigliptin on cardiovascular outcomes in patients with type 2 diabetes (OPTIMUS study)
por: Kim, Eun Heui, et al.
Publicado: (2020)

Management of Blood Pressure in Patients with Type 2 Diabetes Mellitus: A Nationwide Survey in Korean
por: Seo, Mi Hae, et al.
Publicado: (2011)

Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis
por: Dutta, Deep, et al.
Publicado: (2021)

A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus
por: Yang, Sae Jeong, et al.
Publicado: (2021)

Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION)
por: Lee, Byung Wan, et al.
Publicado: (2023)

Gemigliptin, a DPP4 inhibitor, ameliorates nonalcoholic steatohepatitis through AMP-activated protein kinase-independent and ULK1-mediated autophagy
por: Song, Youngmi, et al.
Publicado: (2023)

Ameliorating Effect of Gemigliptin on Renal Injury in Murine Adriamycin-Induced Nephropathy
por: Kim, Da Rae, et al.
Publicado: (2017)

Effect of gemigliptin on cardiac ischemia/reperfusion and spontaneous hypertensive rat models
por: Nam, Dae-Hwan, et al.
Publicado: (2019)

Gemigliptin Alleviates Succinate-Induced Hepatic Stellate Cell Activation by Ameliorating Mitochondrial Dysfunction
por: Nguyen, Giang, et al.
Publicado: (2022)

Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double‐blind randomized controlled trial (INICOM study)
por: Lim, Soo, et al.
Publicado: (2016)

Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects
por: Cho, Yong-Soon, et al.
Publicado: (2018)

Maximal Fat Oxidation Rate during Exercise in Korean Women with Type 2 Diabetes Mellitus
por: Suk, Min Hwa, et al.
Publicado: (2015)

Predictors for diabetic retinopathy in normoalbuminuric people with type 2 diabetes mellitus
por: Ra, Ho, et al.
Publicado: (2012)

Gemigliptin Inhibits Interleukin-1β–Induced Endothelial-Mesenchymal Transition via Canonical-Bone Morphogenetic Protein Pathway
por: Hong, Oak-Kee, et al.
Publicado: (2020)

Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians
por: Iqbal, Ahmed, et al.
Publicado: (2018)

Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways
por: Lee, Nami, et al.
Publicado: (2021)

Time‐ and Dose‐Dependent Association of Statin Use With Risk of Clinically Relevant New‐Onset Diabetes Mellitus in Primary Prevention: A Nationwide Observational Cohort Study
por: Ko, Min Jung, et al.
Publicado: (2019)

The influence of type 2 diabetes mellitus on the expression of inflammatory mediators and tissue inhibitor of metalloproteinases-2 in human chronic periodontitis
por: Kim, Jae-Bung, et al.
Publicado: (2011)

Comparison of the Usefulness of the Updated Homeostasis Model Assessment (HOMA2) with the Original HOMA1 in the Prediction of Type 2 Diabetes Mellitus in Koreans
por: Song, Young Seok, et al.
Publicado: (2016)

Current Management of Type 2 Diabetes Mellitus in Primary Care Clinics in Korea
por: Seo, Da Hea, et al.
Publicado: (2019)

Potentiation of endothelium-dependent vasorelaxation of mesenteric arteries from spontaneously hypertensive rats by gemigliptin, a dipeptidyl peptidase-4 inhibitor class of anti-diabetic drug
por: Kim, Hae Jin, et al.
Publicado: (2018)

Evaluation of Pharmacokinetic Drug Interactions Between Gemigliptin (Dipeptidylpeptidase-4 Inhibitor) and Glimepiride (Sulfonylurea) in Healthy Volunteers
por: Choi, Hee Youn, et al.
Publicado: (2014)

Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice
por: Choi, Seung Hee, et al.
Publicado: (2017)

Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study
por: Lim, Soo, et al.
Publicado: (2023)

Dipeptidyl peptidase-4 inhibitor gemigliptin protects against vascular calcification in an experimental chronic kidney disease and vascular smooth muscle cells
por: Choi, Soon-Youn, et al.
Publicado: (2017)

Extract of Ginkgo Biloba Ameliorates Streptozotocin-Induced Type 1 Diabetes Mellitus and High-Fat Diet-Induced Type 2 Diabetes Mellitus in Mice
por: Rhee, Ki-Jong, et al.
Publicado: (2015)

Current Status of Management in Type 2 Diabetes Mellitus at General Hospitals in South Korea
por: Jung, Jin-Hee, et al.
Publicado: (2015)

Antidiabetic effect of gemigliptin: a systematic review and meta-analysis of randomized controlled trials with Bayesian inference through a quality management system
por: Oh, Hojin, et al.
Publicado: (2021)

Recent Updates on Vascular Complications in Patients with Type 2 Diabetes Mellitus
por: Jung, Chan-Hee, et al.
Publicado: (2020)

A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects
por: Park, Sang-In, et al.
Publicado: (2015)

A Fixed-Dose Combination Of Gemigliptin And Rosuvastatin Exhibits Similar Pharmacokinetics, Pharmacodynamics, And Safety Compared To That Of A Loose Combination In Healthy Subjects
por: Kim, Eunwoo, et al.
Publicado: (2019)

Management of Type 2 Diabetes Mellitus in Older Adults
por: Kim, Kyung Soo, et al.
Publicado: (2012)

An update on diagnosis and therapeutics for type-2 diabetes mellitus
por: Shyamaladevi, Babu, et al.
Publicado: (2023)

Update on Diabetes Mellitus
por: Korc, Murray
Publicado: (2004)

Diabetes Mellitus: An Update
por: Diamantis, Evaggelos
Publicado: (2020)

Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus
por: Kim, Soon Ae, et al.
Publicado: (2011)

Nutritional Intake of Pregnant Women with Gestational Diabetes or Type 2 Diabetes Mellitus
por: Lim, Sun-Young, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_h7hormh7dhm836j84fig3jedag